Turn Therapeutics Inc. (NASDAQ:TTRX) Stock Has Consensus Price Target of $9.00 According to Analysts

Posted by George Bondi on Nov 10th, 2026

Shares of Turn Therapeutics Inc. (NASDAQ:TTRX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $9.00.

TTRX has been the subject of several research analyst reports. Weiss Ratings cut Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. WBB Securities raised shares of Turn Therapeutics from a “sell” rating to a “hold” rating and set a $10.00 price target for the company in a research report on Friday, October 23rd. Zacks Research upgraded shares of Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. Wall Street Zen cut Turn Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Finally, LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a report on Monday, July 20th.

Get Our Latest Stock Report on Turn Therapeutics

Turn Therapeutics Stock Up 3.3%

Shares of NASDAQ TTRX opened at $9.79 on Tuesday. Turn Therapeutics has a 1 year low of $2.57 and a 1 year high of $16.45. The firm has a 50-day simple moving average of $11.70 and a two-hundred day simple moving average of $7.16. The company has a market cap of $298.92 million and a P/E ratio of -33.76. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.21) earnings per share for the quarter. Research analysts anticipate that Turn Therapeutics will post -0.40 earnings per share for the current year.

Hedge Funds Weigh In On Turn Therapeutics

Several large investors have recently made changes to their positions in TTRX. SteelPeak Wealth LLC lifted its stake in shares of Turn Therapeutics by 0.7% in the third quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock worth $3,616,000 after buying an additional 1,819 shares in the last quarter. TD Waterhouse Canada Inc. acquired a new stake in Turn Therapeutics in the 3rd quarter valued at approximately $40,000. Bank of America Corp DE acquired a new position in Turn Therapeutics during the 2nd quarter worth about $103,000. Jefferies Financial Group Inc. acquired a new position in shares of Turn Therapeutics in the second quarter valued at approximately $119,000. Finally, Bridgewater Advisors Inc. acquired a new position in Turn Therapeutics during the 2nd quarter worth $242,000.

Turn Therapeutics Company Profile

(Get Free Report)

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.